No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The 5-HT7 antagonists market is a segment of the Central Nervous System Drugs market. 5-HT7 antagonists are a class of drugs that act on the serotonin receptor 7 (5-HT7) to reduce symptoms of depression, anxiety, and insomnia. These drugs are used to treat a variety of psychiatric and neurological disorders, including major depressive disorder, bipolar disorder, and schizophrenia. They are also used to treat insomnia, as well as to reduce the risk of suicide in patients with depression.
5-HT7 antagonists are typically administered orally, and are available in both generic and branded forms. The market for 5-HT7 antagonists is expected to grow in the coming years, driven by the increasing prevalence of mental health disorders and the growing demand for effective treatments.
Some companies in the 5-HT7 antagonists market include AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Sunovion. Show Less Read more
